NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $24.74 -0.26 (-1.04%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$24.67▼$25.2250-Day Range$20.48▼$25.0052-Week Range$14.56▼$25.25Volume167,253 shsAverage Volume1.15 million shsMarket Capitalization$3.53 billionP/E RatioN/ADividend YieldN/APrice Target$39.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Denali Therapeutics alerts: Email Address Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside57.3% Upside$39.33 Price TargetShort InterestBearish6.11% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.09Based on 9 Articles This WeekInsider TradingSelling Shares$710,274 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.77) to ($2.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.73 out of 5 starsMedical Sector221st out of 924 stocksBiotechnology Industry3rd out of 25 stocks 3.4 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Denali Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.11% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 2.8 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search Interest9 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows8 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $710,274.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.77) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -26.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -26.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsSecure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.Click here for the ticker >>> About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesAugust 21 at 10:27 AM | seekingalpha.comDenali Therapeutics Continues To Have Plenty Of Moving PartsAugust 18, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Earns "Buy" Rating from HC WainwrightAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 16, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives $39.33 Average PT from AnalystsAugust 15, 2024 | investing.comDenali Therapeutics Inc (DNLI)August 14, 2024 | globenewswire.comDenali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous AdministrationAugust 11, 2024 | finance.yahoo.comDNLI Aug 2024 17.500 put (DNLI240816P00017500)August 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Denali Therapeutics (DNLI) and Owens & Minor (OMI)August 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Denali Therapeutics Amid Strategic Moves and Regulatory AdvancementsAugust 5, 2024 | ca.finance.yahoo.comDNLI Aug 2024 17.500 putAugust 4, 2024 | uk.investing.comDenali Therapeutics shares target cut, hold rating maintained by H.C. WainwrightAugust 2, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)August 1, 2024 | msn.comDenali Therapeutics GAAP EPS of -$0.59 beats by $0.11August 1, 2024 | globenewswire.comDenali Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsJuly 8, 2024 | investorplace.com3 Longevity Stocks to Buy for Anti-Aging BreakthroughsJune 6, 2024 | seekingalpha.comDenali: Cash, Big Pharma Partnerships And High Potential For MPS-II Do Not Warrant A BuyJune 3, 2024 | globenewswire.comDenali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesSee More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees364Year Founded2015Price Target and Rating Average Stock Price Target$39.33 High Stock Price Target$90.00 Low Stock Price Target$22.00 Potential Upside/Downside+57.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net MarginsN/A Pretax Margin-46.45% Return on Equity-34.92% Return on Assets-31.70% Debt Debt-to-Equity RatioN/A Current Ratio11.79 Quick Ratio11.79 Sales & Book Value Annual Sales$1.27 million Price / Sales2,813.91 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book3.37Miscellaneous Outstanding Shares142,609,000Free Float131,343,000Market Cap$3.57 billion OptionableOptionable Beta1.40 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Comp: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Comp: $802.29kDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Comp: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Comp: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAEnliven TherapeuticsNASDAQ:ELVNCytokineticsNASDAQ:CYTKREGENXBIONASDAQ:RGNXAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInsiders & InstitutionsCreative PlanningBought 3,458 shares on 8/16/2024Ownership: 0.030%Algert Global LLCSold 55,345 shares on 8/16/2024Ownership: 0.019%Quarry LPSold 500 shares on 8/16/2024Ownership: 0.005%Susquehanna Fundamental Investments LLCBought 11,900 shares on 8/15/2024Ownership: 0.156%Point72 Asia Singapore Pte. Ltd.Bought 8,335 shares on 8/15/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $21.46 at the beginning of 2024. Since then, DNLI stock has increased by 16.5% and is now trading at $25.00. View the best growth stocks for 2024 here. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Thursday, August, 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.09. The firm's revenue for the quarter was down 99.7% on a year-over-year basis. What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' top institutional shareholders include Baillie Gifford & Co. (9.65%), Marshall Wace LLP (1.70%), Bank of New York Mellon Corp (1.08%) and Dimensional Fund Advisors LP (0.99%). Insiders that own company stock include Marc Tessier-Lavigne, Alexander O Schuth, Ryan J Watts, Carole Ho, Vicki L Sato and Steve E Krognes. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP) and Anavex Life Sciences (AVXL). This page (NASDAQ:DNLI) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact ...Crypto 101 Media | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts